SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE
-
Upload
healthegy -
Category
Healthcare
-
view
658 -
download
2
Transcript of SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE
![Page 1: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/1.jpg)
![Page 2: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/2.jpg)
![Page 3: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/3.jpg)
SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE
William J. Link, PhDManaging DirectorVersant Ventures
![Page 4: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/4.jpg)
Update--- Ophthalmic Innovation Cycle & Financial markets
OIS@ASCRS May 5, 2016
William J. Link, PhD
Managing Director
Versant Ventures
![Page 5: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/5.jpg)
Welcome!!
• Thank you for your commitment to innovation in ophthalmology!!!
• Overview of the day….
5
![Page 6: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/6.jpg)
Innovation Cycle-Key Constituents
1. Inventor/entrepreneur/team
2. Clinician-early adopter
3. Financial Partner--Venture Capitalist, etc.
4. Industry leaders- commercial team
![Page 7: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/7.jpg)
OIS@ASCRS 2016 Attendance ~ 500
Innovation Cycle-Key Constituents % Attendance
1. Inventor/entrepreneur/team ~35%
2. Clinician-early adopter ~15%
3. Financial Partner--Venture Capitalist, etc. ~ 5%
4. Industry leaders- commercial team ~25%
Note: Press, consultants, service providers ~ 20%
![Page 8: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/8.jpg)
OIS….quite a journey
• Today is our 12th OIS meeting….
8
![Page 9: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/9.jpg)
OIS….quite a journey
• Today is our 12th OIS meeting….
• Inaugural OIS@AAO meeting 2009 in San Francisco– AAO has been a great partner
9
![Page 10: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/10.jpg)
Ophthalmology Innovation Summit – 2009Palace Hotel
San Francisco, California
![Page 11: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/11.jpg)
OPHTHALMOLOGY INNOVATION SUMMIT Advisory Board
Emmett T. Cunningham, Jr. MD PartnerClarus Ventures
William Link, PhDManaging DirectorVersant Ventures
Anthony AdamisProfessor of Ophthalmology & Visual ScienceUniversity of Illinois
Mark S. Blumenkranz, MDProfessor & ChairmanDept. of OphthalmologyStanford University
Brook ByersPartnerKleiner Perkins Caufield & Byers
Eugene de Juan, Jr., MDFounder & Vice ChairmanForSight Labs, LLC
Angela McFarlanePresident & CEOForSight Labs, LLC
Lutz Giebel, PhDManaging PartnerSV Life Sciences
David Guyer, MDPartnerSV Life Sciences
Roman G. Rubio, MDMedical Director, OphthalmologyGenentech
Charles WardenManaging DirectorVersant Ventures
Gilbert Kliman, MDGeneral Partner, Life SciencesInterWest Partners
Samir Patel, MDPresident & CEOOphthoTech
Scott M. Whitcup, MDEVP, R&D, and Chief Scientific OfficerAllergan, Inc.
![Page 12: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/12.jpg)
OIS….quite a journey
• Today is our 12th OIS meeting….
• Inaugural OIS@AAO meeting 2009 in San Francisco– AAO has been a great partner
• Inaugural OIS@ASCRS meeting in 2012 in Chicago– ASCRS has been a great partner
12
![Page 13: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/13.jpg)
13
![Page 14: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/14.jpg)
14
![Page 15: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/15.jpg)
15
![Page 16: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/16.jpg)
OIS….quite a journey
• Today is our 12th OIS meeting….
• Inaugural OIS@AAO meeting 2009 in San Francisco– AAO has been a great partner
• Inaugural OIS@ASCRS meeting in 2012 in Chicago– ASCRS has been a great partner
• Inaugural OIS@ASRS meeting will be this year…August 8th in San Francisco– ASRS will be a great partner
16
![Page 17: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/17.jpg)
Innovation in Ophthalmology
• Innovation Cycle- review of the stages
• Principles of Innovation
• Constituents involved in (required for) innovation
• External environment—impact on innovation
17
![Page 18: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/18.jpg)
Innovation Cycle – Surgical Ophthalmic Technologies
Observation &
InventionProduct Dev/Pre-Clinical
Iterate/ Refine
Human Proof of Concept
Iterate/ Refine
CE Mark/ OUS Market
Dev.
FDA Approval
U.S./Global Market Dev.
Source: Market Scope
![Page 19: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/19.jpg)
Innovation Cycle – Surgical Ophthalmic Technologies
1 2 3 4 5 6 7 8 9 10 11 12
Observation/Invention
Years
Product Dev/Pre-Clinical Phase – 1-3 yrs
Human Proof of Concept – 1-3 yrs
FDA Approval / U.S. / Launch
Successful Global Commercialization
FDA Study - 1-2 yrs 510K, 4-6 yrs PMA
Refinement – 1-2 yrs
CE Mark/OUS Market Dev
Va
lue
Cre
ati
on
![Page 20: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/20.jpg)
Lab Research
Pre-clinical In vitro
In vivo
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
FDA Approval
OUS Regulatory Approvals
Global Market Dev.
Innovation Cycle – Ophthalmic Pharma & Biopharma
Source: Market Scope
![Page 21: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/21.jpg)
Innovation Cycle – Ophthalmic Pharma and Biopharma
1 2 3 4 5 6 7 8 9 10 11 12
Laboratory Research
Years
Pre-clinical In vitro & In vivo – 1-3 yrs
Phase I Clinical Trials – 1-3 yrs
OUS Approval
Global Commercialization
FDA Approval
Phase II Clinical Trials– 1-3 yrs
Phase III Clinical Trials 2-4 yrs
Va
lue
Cre
ati
on
![Page 22: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/22.jpg)
22
Principles of Innovation
![Page 23: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/23.jpg)
23
Principles of Innovation
• Focus on important issues (big markets)
![Page 24: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/24.jpg)
24
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
![Page 25: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/25.jpg)
25
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
![Page 26: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/26.jpg)
26
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
• Try things-when in doubt….try it
![Page 27: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/27.jpg)
27
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
• Try things-when in doubt….try it
• Be willing to fail
![Page 28: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/28.jpg)
28
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
• Try things—when in doubt….try it
• Be willing to fail
• Don’t be paralyzed by mistakes
![Page 29: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/29.jpg)
29
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
• Try things—when in doubt….try it
• Be willing to fail
• Don’t be paralyzed by mistakes
• Be skilled
![Page 30: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/30.jpg)
30
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
• Try things—when in doubt….try it
• Be willing to fail
• Don’t be paralyzed by mistakes
• Be skilled
• Be aggressive and assertive, but not arrogant
![Page 31: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/31.jpg)
31
Principles of Innovation
• Focus on important issues (big markets)
• Seek the truth
• Be disciplined
• Try things—when in doubt….try it
• Be willing to fail
• Don’t be paralyzed by mistakes
• Be skilled
• Be aggressive and assertive, but not arrogant
• Professionalism pays off
![Page 32: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/32.jpg)
32
Principles of Innovation
• Focus on important issues (big markets)• Seek the truth• Be disciplined• Try things—when in doubt….try it• Be willing to fail• Don’t be paralyzed by mistakes• Be skilled• Be aggressive and assertive, but not arrogant• Professionalism pays off
![Page 33: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/33.jpg)
33
Where Does Innovation Happen?
• Wherever the innovators are….and where the culture fosters innovation
• Corporate Culture of Innovation– Knows that innovation drives value
– Does not punish mistakes
– Knows it is NOT all about My ideas…others’ ideas have merit
– Balances internal with external innovation
– “Not invented here” attitude stifles innovation
![Page 34: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/34.jpg)
Innovation Cycle-Key Contributors
1. Inventor/entrepreneur/team
2. Clinicians-early adopters
3. Financial Partners--Venture Capitalist, etc.
4. Industry leaders- commercial team
![Page 35: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/35.jpg)
External Environment—Impact on Life Cycle
• Public Markets
• Venture Funding
• M&A Activities
• Outlook….
35
![Page 36: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/36.jpg)
Trends in HealthcareInvestments and Exits 2016Investor Confidence and Innovation Drive Healthcare Venture to New Heights
Written by
Jonathan NorrisManaging DirectorSilicon Valley BankM [email protected]@jonnysvb
Paul SchuberValuations AssociateSVB Analytics
Caitlin TolmanSenior AssociateSilicon Valley Bank
![Page 37: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/37.jpg)
37
2015: Another Banner Year for Healthcare
At the start of 2015, it was hard to imagine that we would have another year as successful as 2014. And yet, by most measures, 2015 came very close.
.
Despite the slowdown in Q4, the healthcare industry is poised for a strong 2016, though activity likely will not match 2015.
![Page 38: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/38.jpg)
38
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 3Q'15$0
$5
$10
$15
$20
$25
$30
$35
$40
$45
$50
$55
$60
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
$ B
illio
nsU.S. Healthcare Venture Investment Hits 15-Year High Healthcare as Percentage of Total Venture Investment
Venture investments in healthcare were projected to reach $9.4 billion in 2015, the highest level since 2000.
Biopharma venture investments reached a record $7 billion, and device remained steady at $2.4 billion .
$105
Total VC$ % Biopharma % Device
*Projected total for 2015Source: PricewaterhouseCoopers, Thomson Reuters and SVB proprietary dataThomson Reuters data includes life science and dx/tools in biopharma and device categories.
2015*
![Page 39: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/39.jpg)
39
0
40
80
120
46 45 4517
# of
Dea
ls
Biopharma Series A Investment Dollars Surge while Device and Dx/Tools Struggle
Source: VentureSource, PitchBook, CB Insights and SVB proprietary data
2012 2013 2014 2015
0
40
80
12076
5981 97
# of
Dea
ls
Total Series A ($M) $776 $1,102 $823 $1,871
CVC Deals % / # 22% / 17 29% / 17 27% / 22 29% / 28
BIOPHARMA
0
40
80
120
35 34 3922
# of
Dea
ls
Total Series A ($M) $212 $215 $327 $96
CVC Deals % / # 9% / 3 18% / 6 15% / 6 32% / 7
DEVICE
Total Series A ($M) $331 $257 $354 $165
CVC Deals % / # 4% / 2 11% / 5 9% / 4 24% / 4
DX/TOOLS
U.S. Company Formation: Deals and Investments in Series A
![Page 40: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/40.jpg)
40
Healthcare Venture Exits:M&A Climate Improves as IPOs Slow
![Page 41: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/41.jpg)
41
2009 2010 2011 2012 2013 2014 20150.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
22.0
24.0
Tota
l Val
ue ($
Bill
ions
)2015 Sets Record for Healthcare Investment Returns
Pre-MoneyIPO Value ($B) $0.1 $1.8 $1.2 $2.1 $8.8 $12.1 $11.6
Big Exit Upfront
Payments ($B)$4.5 $4.1 $6.6 $4.3 $5.4 $8.0 $9.9
Big Exit Milestones
($B)$0.9 $1.1 $1.0 $1.8 $0.8 $1.0 $2.2
Pre-Money IPO Value
Big Exit Milestones to be Earned
Big Exit Upfront Payments
Source: Investment bank research, VentureSource press releases, CB Insights, and discussions with life science professionals
Potential Distributions from VC-Backed IPOs and Big Exit M&A 2009-15
![Page 42: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/42.jpg)
42
2016 Outlook: 2015 Will Be a Hard Act to Follow
As 2015 closed, we saw some decline in exit activity and investor interest that indicate things are slowing. Here are our predictions for 2016:
• The biopharma IPO window should remain open, but there will be fewer IPOs,
• M&A will continue on pace as acquirers seek biopharma companies to replenish their pipeline
• Device IPO activity will decline, M&A activity will likely remain stable. We believe this will lead to increased deal values and returns to investors.
• We anticipate continued acquisition flurries, similar to Q3 2015, as acquirers are pressured to innovate.
![Page 43: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/43.jpg)
Innovation in Ophthalmology--Financial Outlook
43
![Page 44: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/44.jpg)
Innovation in Ophthalmology--Financial Outlook
• Venture financing in healthcare has regained momentum…
44
![Page 45: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/45.jpg)
Innovation in Ophthalmology--Financial Outlook
• Venture financing in healthcare has regained momentum…
• IPO activity picked up in 2013 and 2014….remained strong in 2015…will be more moderate in 2016
45
![Page 46: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/46.jpg)
Innovation in Ophthalmology--Financial Outlook
• Venture financing in healthcare has regained momentum…
• IPO activity picked up in 2013 and 2014….remained strong in 2015…will be more moderate in 2016
• M&A activity remains strong, but is impacted by industry changes/consolidation
46
![Page 47: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/47.jpg)
Innovation in Ophthalmology--Financial Outlook
• Venture financing in healthcare has regained momentum…
• IPO activity picked up in 2013 and 2014….remained strong in 2015…will be more moderate in 2016
• M&A activity remains strong, but is impacted by industry changes/consolidation
• Relative Attractiveness of the Ophthalmic Sector is solid….
47
![Page 48: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/48.jpg)
Innovation in Ophthalmology--Financial Outlook
• Venture financing in healthcare has regained momentum…
• IPO activity picked up in 2013 and 2014….remained strong in 2015…will be more moderate in 2016
• M&A activity remains strong, but is impacted by industry changes/consolidation
• Relative Attractiveness of the Ophthalmic Sector is solid….
48
![Page 49: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/49.jpg)
Innovation in Ophthalmology
![Page 50: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/50.jpg)
Innovation in Ophthalmology
• Still immense unmet needs
![Page 51: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/51.jpg)
Innovation in Ophthalmology
• Still immense unmet needs
• Innovation resources focused where they are rewarded
![Page 52: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/52.jpg)
Innovation in Ophthalmology
• Still immense unmet needs
• Innovation resources focused where they are rewarded
• Key Constituents….entrepreneurs; clinicians; VCs and Industry…..strong and more connected than ever
![Page 53: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/53.jpg)
Innovation in Ophthalmology
• Still immense unmet needs
• Innovation resources focused where they are rewarded
• Key Constituents….entrepreneurs; clinicians; VCs and Industry…..strong and more connected than ever
• Innovation in the ophthalmic sector is gaining, not losing momentum
![Page 54: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/54.jpg)
Innovation in Ophthalmology
• Still immense unmet needs
• Innovation resources focused where they are rewarded
• Key Constituents….entrepreneurs; clinicians; VCs and Industry…..strong and more connected than ever
• Innovation in the ophthalmic sector is gaining, not losing momentum
• Thanks to all who are committed….because when we do well, many people benefit!!
![Page 55: SUMMIT KICK OFF WITH OPHTHALMOLOGY INNOVATION CYCLE & FINANCING UPDATE](https://reader035.fdocuments.net/reader035/viewer/2022070515/58782ced1a28abef5d8b5e49/html5/thumbnails/55.jpg)
Thank you….